Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
18
05
2022
accepted:
21
07
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Pirfenidone (PFD) is widely used in patients with idiopathic pulmonary fibrosis (IPF) and its adverse effects, such as nausea and photosensitivity, are well known. Many patients with IPF have reduced doses or even cessation of PFD because of its side-effects. No solutions have been found for these side-effects because the current mechanistic insights are insufficient. Using the results of real-world data analysis from the US Food and Drug Administration Adverse Events Reporting System, we hypothesised that PFD-related symptoms may be similar to pellagra. Reverse translational experiments using female BALB/c mice were performed to validate and estimate this hypothesis. Niacin and its metabolite responses were compared between patients with IPF treated with PFD and those treated without PFD. The pellagra hypothesis was translated from real-world data analysis. Pharmacological and comprehensive genetic investigations showed that PFD caused pellagra-related nausea and photosensitivity in a mouse model, which may have been mediated by the actions of nicotinamide PFD may cause pellagra or pellagra-like symptoms such as photosensitivity. Further studies are required to investigate whether niacin prevents pellagra-like symptoms caused by PFD in patients with IPF.
Sections du résumé
Background
UNASSIGNED
Pirfenidone (PFD) is widely used in patients with idiopathic pulmonary fibrosis (IPF) and its adverse effects, such as nausea and photosensitivity, are well known. Many patients with IPF have reduced doses or even cessation of PFD because of its side-effects. No solutions have been found for these side-effects because the current mechanistic insights are insufficient.
Methods
UNASSIGNED
Using the results of real-world data analysis from the US Food and Drug Administration Adverse Events Reporting System, we hypothesised that PFD-related symptoms may be similar to pellagra. Reverse translational experiments using female BALB/c mice were performed to validate and estimate this hypothesis. Niacin and its metabolite responses were compared between patients with IPF treated with PFD and those treated without PFD.
Results
UNASSIGNED
The pellagra hypothesis was translated from real-world data analysis. Pharmacological and comprehensive genetic investigations showed that PFD caused pellagra-related nausea and photosensitivity in a mouse model, which may have been mediated by the actions of nicotinamide
Conclusions
UNASSIGNED
PFD may cause pellagra or pellagra-like symptoms such as photosensitivity. Further studies are required to investigate whether niacin prevents pellagra-like symptoms caused by PFD in patients with IPF.
Identifiants
pubmed: 36299372
doi: 10.1183/23120541.00245-2022
pii: 00245-2022
pmc: PMC9589320
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: T. Kuroita, N. Susai and T. Yoshioka are employees of Shionogi & Co., Ltd. The other authors declare no competing interests.
Références
J Nutr Sci Vitaminol (Tokyo). 2015;61 Suppl:S145-7
pubmed: 26598832
Biol Pharm Bull. 2020;43(3):362-365
pubmed: 32115497
Circ Res. 2005 Oct 28;97(9):908-15
pubmed: 16179585
Photodermatol Photoimmunol Photomed. 2021 Mar;37(2):99-104
pubmed: 33471377
Sci Rep. 2015 Mar 10;5:8906
pubmed: 25752528
Lab Invest. 2007 Jan;87(1):49-55
pubmed: 17075575
Nihon Yakurigaku Zasshi. 2008 Aug;132(2):83-8
pubmed: 18689956
Eur J Pharmacol. 2007 Jan 5;554(1):34-9
pubmed: 17109847
J Oleo Sci. 2017 Jun 1;66(6):591-599
pubmed: 28515378
Biosci Microbiota Food Health. 2022;41(2):73-82
pubmed: 35433165
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):148-157
pubmed: 33093778
BMJ Open Respir Res. 2016 Jan 12;3(1):e000105
pubmed: 26835133
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374120
Am J Clin Nutr. 1968 Jan;21(1):98-106
pubmed: 4230098
Br J Dermatol. 2011 Jun;164(6):1188-200
pubmed: 21128910
Am J Physiol Lung Cell Mol Physiol. 2022 Aug 1;323(2):L193-L205
pubmed: 35787697
Lipids Health Dis. 2013 Oct 23;12:151
pubmed: 24148690
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Sci Transl Med. 2013 Oct 9;5(206):206ra140
pubmed: 24107779
Respir Investig. 2015 Sep;53(5):232-41
pubmed: 26344613
Int J Dermatol. 2004 Jan;43(1):1-5
pubmed: 14693013
Expert Opin Drug Saf. 2006 Mar;5(2):231-49
pubmed: 16503745
PLoS One. 2018 Oct 9;13(10):e0204648
pubmed: 30300381
Nutrients. 2020 Apr 17;12(4):
pubmed: 32316662
Sci Rep. 2016 May 20;6:26375
pubmed: 27199286
Ther Deliv. 2021 Jul;12(7):515-522
pubmed: 34139888
Br J Nutr. 2022 Apr 14;127(7):961-971
pubmed: 34078491
J Dermatol Sci. 2017 Mar;85(3):186-196
pubmed: 28024685
J Nutr. 1994 Sep;124(9):1597-603
pubmed: 8089727
Exp Lung Res. 1994 Jul-Aug;20(4):263-81
pubmed: 7527336
Eur Respir J. 2010 Apr;35(4):821-9
pubmed: 19996196
Psychosomatics. 2010 Mar-Apr;51(2):93-7
pubmed: 20332283
Sci Rep. 2013 Oct 17;3:2973
pubmed: 24131900
Front Pharmacol. 2021 Sep 21;12:635293
pubmed: 34621164
ERJ Open Res. 2018 Oct 19;4(4):
pubmed: 30364407
Pharmacol Biochem Behav. 1993 Aug;45(4):817-21
pubmed: 8415820